NO20050786L - Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse - Google Patents

Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse

Info

Publication number
NO20050786L
NO20050786L NO20050786A NO20050786A NO20050786L NO 20050786 L NO20050786 L NO 20050786L NO 20050786 A NO20050786 A NO 20050786A NO 20050786 A NO20050786 A NO 20050786A NO 20050786 L NO20050786 L NO 20050786L
Authority
NO
Norway
Prior art keywords
methods
ismns
ismn
reduction
therapeutically effective
Prior art date
Application number
NO20050786A
Other languages
English (en)
Inventor
John G Devane
Paul Stark
John Kelly
Jackie Butler
Original Assignee
Biovail Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Inc filed Critical Biovail Lab Inc
Publication of NO20050786L publication Critical patent/NO20050786L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

Foreliggende oppfinnelse angår uformninger av isosorbidmononitrater (ISMN'er) med forsinket begynnelse og forlenget frigjøring, samt fremgangsmåter for anvendelse av disse ved behandling, forebygging, redusering, reversering og/eller håndtering av nitrattoleranse og/eller kardiovaskulære tilstander. Spesielt er foreliggende oppfinnelse rettet mot utformninger med forsinket begynnelse og forlenget frigjøring for administrering én gang daglig, som (1) tilfører et individ en terapeutisk effektiv mengde av ISMN'er i løpet av de tidlige morgentimer før og etter oppvåkning, (2) fortsetter å tilføre terapeutisk effektive mengder av ISMN i løpet av de våkne timer om dagen, og (3) tilveiebringer en reduksjon eller utvasking av ISMN-plasmanivåene under behandling, forebygging, redusering, reversering og/eller håndtering av nitrattoleranse.
NO20050786A 2002-08-08 2005-02-14 Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse NO20050786L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/214,345 US20040029959A1 (en) 2002-08-08 2002-08-08 Isosorbide mononitrate compositions and methods of their use
PCT/IB2003/004245 WO2004014849A2 (en) 2002-08-08 2003-08-08 Isosorbide mononitrate compositions and methods of their use

Publications (1)

Publication Number Publication Date
NO20050786L true NO20050786L (no) 2005-05-03

Family

ID=31494642

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050786A NO20050786L (no) 2002-08-08 2005-02-14 Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse

Country Status (10)

Country Link
US (1) US20040029959A1 (no)
EP (1) EP1545550A4 (no)
JP (1) JP2005535700A (no)
AU (1) AU2003263515A1 (no)
CA (1) CA2495071A1 (no)
IL (1) IL166299A0 (no)
MX (1) MXPA05001559A (no)
NO (1) NO20050786L (no)
PL (1) PL375274A1 (no)
WO (1) WO2004014849A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106093247A (zh) * 2016-08-19 2016-11-09 蚌埠丰原涂山制药有限公司 一种检测单硝酸异山梨酯中乙酸乙酯残留量的方法
CN107582540B (zh) * 2017-09-19 2018-06-05 扬子江药业集团上海海尼药业有限公司 一种单硝酸异山梨酯胶囊及其制备方法
CN107802610B (zh) * 2017-11-22 2020-10-20 乐普药业股份有限公司 一种单硝酸异山梨酯缓释片及制备方法
CN112121025B (zh) * 2019-06-24 2022-05-31 翰宇药业（武汉）有限公司 一种单硝酸异山梨酯缓释片剂及其制备方法
CN110559269A (zh) * 2019-08-15 2019-12-13 仁和堂药业有限公司 一种单硝酸异山梨酯片剂及其质量检测方法
CN110478328A (zh) * 2019-08-15 2019-11-22 仁和堂药业有限公司 单硝酸异山梨酯片的制备工艺

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS578490Y2 (no) * 1977-08-12 1982-02-18
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
DE3333639A1 (de) * 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4767808A (en) * 1984-10-05 1988-08-30 Hercon Laboratories Corporation Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4681584A (en) * 1985-05-03 1987-07-21 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4655766A (en) * 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
US5141752A (en) * 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
EP0249343B1 (en) * 1986-06-13 1992-01-08 Alza Corporation Moisture activation of transdermal drug delivery system
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
ATE71293T1 (de) * 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
CH672888A5 (no) * 1986-11-07 1990-01-15 Mepha Ag
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5071656A (en) * 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4956181A (en) * 1987-05-08 1990-09-11 Eastman Kodak Nitrate therapy for angina pectoris
EP0290262A3 (en) * 1987-05-08 1990-12-12 EASTMAN KODAK COMPANY (a New Jersey corporation) Improved nitrate therapy for angina pectoris
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
JPH11501026A (ja) * 1995-02-28 1999-01-26 アストラ・アクチエボラーグ イソソルビド−５−モノナイトレートの使用
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
BR9905261A (pt) * 1999-09-30 2001-07-24 Libbs Farmaceutica Ltda Uma nova associação medicamentosa de liberação programada
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
JP4696210B2 (ja) * 2000-06-07 2011-06-08 トーアエイヨー株式会社 イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法

Also Published As

Publication number Publication date
MXPA05001559A (es) 2005-08-19
IL166299A0 (en) 2006-01-15
PL375274A1 (en) 2005-11-28
US20040029959A1 (en) 2004-02-12
WO2004014849A2 (en) 2004-02-19
EP1545550A4 (en) 2011-04-13
JP2005535700A (ja) 2005-11-24
CA2495071A1 (en) 2004-02-19
AU2003263515A1 (en) 2004-02-25
EP1545550A2 (en) 2005-06-29
WO2004014849A3 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
NO20050786L (no) Isosorbidmononitratblandinger og fremgangsmater for deres anvendelse
TW283645B (no)
EP1273298A3 (en) Ritonavir in combination with an additional HIV protease inhibitor for treating aids
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
TW200505439A (en) Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight loss agents
WO2005107793A3 (en) Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
IL158559A0 (en) Acne treatment
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
NO20051426L (no) Behandling av melanom ved reduksjon i clusterin-nivaer
WO2005044194A3 (en) TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2003018061A1 (fr) Medicaments contenant un inhibiteur de la chymase et un inhibiteur de l'ace comme principes actifs
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2004000227A3 (en) Use of thio-oxindole derivatives in treatment of skin disorders
DK1581235T3 (da) Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi
HK1099918A1 (en) Composition and use for prevention or treatment of stomatitis
WO2003057172A3 (en) Topical application of alpha-dfmo and anti-inflammatory drug for treatment of actinic keratoses
HK1087328A1 (en) Therapeutic composition for autoimmune conditions
WO2002045704A3 (en) Prevention and treatment of tachyphylactic response
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
BR0308396A (pt) Processo de tratamento de diabetes mellitus incluindo condições associadas com diabetes mellitus e complicações de diabetes mellitus
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application